MX2015012771A - Procedimiento de tratamiento de la deficiencia de vitamina b12. - Google Patents

Procedimiento de tratamiento de la deficiencia de vitamina b12.

Info

Publication number
MX2015012771A
MX2015012771A MX2015012771A MX2015012771A MX2015012771A MX 2015012771 A MX2015012771 A MX 2015012771A MX 2015012771 A MX2015012771 A MX 2015012771A MX 2015012771 A MX2015012771 A MX 2015012771A MX 2015012771 A MX2015012771 A MX 2015012771A
Authority
MX
Mexico
Prior art keywords
vitamin
deficiency
present
treatment
compounds
Prior art date
Application number
MX2015012771A
Other languages
English (en)
Inventor
John Mccarty
Original Assignee
Pharmaceutical Productions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaceutical Productions Inc filed Critical Pharmaceutical Productions Inc
Publication of MX2015012771A publication Critical patent/MX2015012771A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere en general a una composición farmacéutica de vitamina B12 y a un procedimiento de uso de la misma para el tratamiento de la deficiencia de vitamina B12 y los diversos trastornos que están relacionados con dicha deficiencia. En realizaciones particulares, la presente invención se refiere a métodos de tratamiento que comprenden la administración sublingual o bucal de una composición de vitamina B12 útiles en la práctica de tal tratamiento. La presente invención se refiere a composiciones que incluyen uno o más compuestos de vitamina B12, propilenglicol, un adsorbente sólido y un excipiente sólido soluble en agua, en las que los compuestos de vitamina B12 están en una solución de propilenglicol.
MX2015012771A 2013-03-14 2014-03-14 Procedimiento de tratamiento de la deficiencia de vitamina b12. MX2015012771A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782246P 2013-03-14 2013-03-14
PCT/US2014/027412 WO2014152504A1 (en) 2013-03-14 2014-03-14 Method of treating vitamin b12 deficiency

Publications (1)

Publication Number Publication Date
MX2015012771A true MX2015012771A (es) 2016-05-31

Family

ID=50543352

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012771A MX2015012771A (es) 2013-03-14 2014-03-14 Procedimiento de tratamiento de la deficiencia de vitamina b12.

Country Status (9)

Country Link
US (1) US20160000716A1 (es)
EP (1) EP2968117A1 (es)
JP (1) JP2016513694A (es)
AU (1) AU2014239651A1 (es)
BR (1) BR112015023368A2 (es)
CA (1) CA2906060A1 (es)
MX (1) MX2015012771A (es)
RU (1) RU2015140463A (es)
WO (1) WO2014152504A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180185270A1 (en) * 2015-06-08 2018-07-05 Zim Laboratories Limited Mucosal delivery of vitamin b12
JP6650650B2 (ja) 2017-12-21 2020-02-19 国立大学法人大阪大学 神経系疾患治療剤
CN114073683A (zh) * 2021-09-27 2022-02-22 广州汇元医药科技有限公司 一种维生素口溶膜剂及其制备方法
WO2023079445A1 (en) * 2021-11-03 2023-05-11 Lupin Limited Pharmaceutical composition of low dose vitamin b12

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765167B2 (en) * 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
KR20040098009A (ko) * 2002-03-06 2004-11-18 교와 핫꼬 고교 가부시끼가이샤 구강 내 속붕괴성 정제
WO2005094842A1 (en) * 2004-03-30 2005-10-13 Transition Therapeutics Inc. Vitamin b12-containing compositions and methods of use
WO2005105040A2 (en) * 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
WO2013028333A1 (en) * 2011-08-25 2013-02-28 Purebrands LLC Edible strips

Also Published As

Publication number Publication date
AU2014239651A1 (en) 2015-10-15
BR112015023368A2 (pt) 2017-07-18
EP2968117A1 (en) 2016-01-20
RU2015140463A (ru) 2017-04-18
US20160000716A1 (en) 2016-01-07
WO2014152504A1 (en) 2014-09-25
JP2016513694A (ja) 2016-05-16
CA2906060A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
MX2017002321A (es) Compuestos que contienen nitrogeno triciclico para tratar infeccion por neisseria gonorrhoeae.
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2015012771A (es) Procedimiento de tratamiento de la deficiencia de vitamina b12.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
MX2018005134A (es) Formulacion de factor viii (fviii).
IN2013MU03428A (es)
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.